Philippa C. Marrack - Nanotechnology

Author Information

Philippa C. Marrack is associated with the Department of Biomedical Research at National Jewish Health, located in Denver, Colorado, USA. She is a prominent researcher with a focus on immunology and virology, contributing significantly to the understanding of viral mutations and cancer immunotherapy.

Research Contributions

Philippa C. Marrack has made substantial contributions to the fields of immunology and virology. Her research has focused on understanding the mutations in SARS-CoV-2 variants, their impact on virus infectivity, and implications for vaccine efficacy. Additionally, she has worked on cancer immunotherapy, exploring neoantigen prioritization and immune feature discovery. Her studies on the structural basis of viral mutations and their interaction with immune cells have provided valuable insights into both infectious diseases and cancer treatment.

Aliases

Philippa C. Marrack is also known by several aliases, including P Marrack, P. Marrack, P C Marrack, Philippa C. Marrack, Pippa Marrack, and Philippa Marrack.

Publication and Citation Metrics

Metric	Value
Total Papers	537
Total Citations	60,249
h-index	127

Publications:

SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity

DOI: 10.3389/fimmu.2022.825256

Year: 2022

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy

DOI: 10.1080/2162402X.2020.1868130

Year: 2021

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2

DOI: 10.1038/s41422-021-00496-8

Year: 2021

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro

DOI: 10.1080/19420862.2021.1919285

Year: 2021

The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines

DOI: 10.1101/2021.08.25.457692

Year: 2021

Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer

DOI: 10.1073/pnas.2100588118

Year: 2021

The basis of a more contagious 501Y.V1 variant of SARS-COV-2

DOI: 10.1101/2021.02.02.428884

Year: 2021

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro

DOI: 10.1101/2021.02.16.431305

Year: 2021

Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.

DOI: 10.1007/s11427-020-1888-1

Year: 2021

Lysosomal cathepsin creates chimeric epitopes for diabetogenic CD4 T cells via transpeptidation

DOI: 10.1084/jem.20192135

Year: 2021

Why is Material Property Data Important in Nanotechnology?

What is the Future of Nanotechnology in Furniture?

How Does Size Affect Electrical Properties?

How Can Nanotechnology Improve Wind Turbines?

What are the Challenges of Using Social Networks in Nanotechnology?

What are the Challenges in Nanotechnology Imaging?

What Determines the Accuracy of Models in Nanotechnology?

What are Multifunctional Devices in Nanotechnology?

Why Do These Skill Gaps Exist?

What Are the Challenges in Validating Theories?

Partnered Content Networks

Relevant Topics